Atossa Therapeutics, Inc. ATOS NASDAQ · Healthcare · United States
$1.60 -8.86% -$0.16
Summary
48 / 100 · Bulios Score
What speaks for it
- It has no debt and holds $20.6M in cash.
What to watch
- It passes only 0 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $34.7M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $42.5 is 2,565% above today's price. 80% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.